If your email program has trouble displaying this email, view as a webpage.

Virtual Town Hall Series - Test Development and Validation During Public Health Emergencies (COVID-19 and Monkeypox)

On Wednesday, September 28, 2022, from 12:05 to 1 p.m. ET, the U.S. Food and Drug Administration (FDA) will host the next session of the virtual town hall series on test development and validation during public health emergencies. Topics will cover both SARS-CoV-2 (COVID-19) and monkeypox. No registration required.

Panelists include:

• Timothy Stenzel, M.D., Ph.D., Director of the Office of In Vitro Diagnostics
• Toby Lowe, Associate Director for Regulatory Programs, Office of In Vitro Diagnostics
• Kristian Roth, Ph.D., Deputy Director of the Division of Microbiology Devices, Office of In Vitro Diagnostics

There will be an opportunity to ask questions live on the call, and questions may also be submitted in advance by emailing CDRHWebinars@fda.hhs.gov.

• Submit questions by 12 p.m. ET on Monday, September 26, 2022.

In the subject line of the email, type “Questions for the Virtual Town Hall Series - Test Development and Validation During Public Health Emergencies” and clearly indicate whether your question is about COVID-19 or monkeypox.

Previous Virtual Town Halls

• Recordings, printable slides, and transcripts from previous Town Halls are available on the FDA website.

Questions?

• See the FAQs on Testing for SARS-CoV-2.
• See the FAQs on Testing for Monkeypox.
• For general questions about this town hall series, contact Division of Industry and Consumer Education.
• For specific questions about COVID-19 diagnostic development, contact COVID19DX@fda.hhs.gov.
• For specific questions about monkeypox diagnostic development, contact MPXDx@fda.hhs.gov.